About Hummingbird Bioscience
Hummingbird Bioscience is a company based in Singapore (Singapore) founded in 2015 by Lan Zhang and Jerome Boyd-Kirkup.. Hummingbird Bioscience has raised $150 million across 6 funding rounds from investors including SK, Frazier Healthcare Partners and Novo Holdings. Hummingbird Bioscience offers products and services including ADC Platform and Antibody Platform. Hummingbird Bioscience operates in a competitive market with competitors including ALX Oncology, TScan Therapeutics, Lyell Immunopharma, Alpine Immune Sciences and Alector, among others.
- Headquarter Singapore, Singapore
- Founders Lan Zhang, Jerome Boyd-Kirkup
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$150 M (USD)
in 6 rounds
-
Latest Funding Round
$125 M (USD), Series C
May 17, 2021
-
Investors
SK
& 22 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Hummingbird Bioscience
Hummingbird Bioscience offers a comprehensive portfolio of products and services, including ADC Platform and Antibody Platform. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Platform for developing antibody-drug conjugates targeting cancer.
Technology for engineering precision antibody therapeutics.
Funding Insights of Hummingbird Bioscience
Hummingbird Bioscience has successfully raised a total of $150M across 6 strategic funding rounds. The most recent funding activity was a Series C round of $125 million completed in May 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 6
- Last Round Series C — $125.0M
- First Round First Round
- Investors Count 23
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May, 2021 | Amount | Series C - Hummingbird Bioscience | Valuation | Novo Holdings | |
| May, 2020 | Amount | Series B - Hummingbird Bioscience | Valuation | SK | |
| Dec, 2019 | Amount | Series B - Hummingbird Bioscience | Valuation | GNTech Venture Capital , Mirae Asset Venture |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Hummingbird Bioscience
Hummingbird Bioscience has secured backing from 23 investors, including venture fund and institutional investors. Prominent investors backing the company include SK, Frazier Healthcare Partners and Novo Holdings. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity and venture capital fund focused on the healthcare sector
|
Founded Year | Domain | Location | |
|
Healthcare sector private equity investments are managed by the firm.
|
Founded Year | Domain | Location | |
|
Investments in healthcare startups are managed by Octagon Capital Advisors.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Hummingbird Bioscience
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Hummingbird Bioscience
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Hummingbird Bioscience Comparisons
Competitors of Hummingbird Bioscience
Hummingbird Bioscience operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as ALX Oncology, TScan Therapeutics, Lyell Immunopharma, Alpine Immune Sciences and Alector, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
ALX Oncology is focused on advancing cancer treatment therapies.
|
|
| domain | founded_year | HQ Location |
T cell-based treatments for immunological and oncological disorders are developed.
|
|
| domain | founded_year | HQ Location |
CAR-T and TIL immunotherapies for solid tumors are developed.
|
|
| domain | founded_year | HQ Location |
Developer of immunotherapies to treat cancer and autoimmune disorders
|
|
| domain | founded_year | HQ Location |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Hummingbird Bioscience
Frequently Asked Questions about Hummingbird Bioscience
When was Hummingbird Bioscience founded?
Hummingbird Bioscience was founded in 2015 and raised its 1st funding round 2 years after it was founded.
Where is Hummingbird Bioscience located?
Hummingbird Bioscience is headquartered in Singapore, Singapore.
Is Hummingbird Bioscience a funded company?
Hummingbird Bioscience is a funded company, having raised a total of $150M across 6 funding rounds to date. The company's 1st funding round was a Series B of $19M, raised on May 03, 2017.
What does Hummingbird Bioscience do?
The company was founded in 2015 in Singapore and operates in the biotechnology sector. Antibodies for cancer therapy are developed through systems immunology and computational structural biology. Platform technology is utilized for the design of therapeutic antibodies. The pipeline includes HMBD-001, a monoclonal antibody, and HMBD-002, an anti-VISTA monoclonal antibody targeted at cancer treatment.
Who are the top competitors of Hummingbird Bioscience?
Hummingbird Bioscience's top competitors include Alector, Lyell Immunopharma and Alpine Immune Sciences.
What products or services does Hummingbird Bioscience offer?
Hummingbird Bioscience offers ADC Platform and Antibody Platform.
Who are Hummingbird Bioscience's investors?
Hummingbird Bioscience has 23 investors. Key investors include SK, Frazier Healthcare Partners, Novo Holdings, Octagon Capital Advisors, and EDBI.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.